{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:12:49Z","timestamp":1791353569913,"version":"4.3.1"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2021,2,6]],"date-time":"2021-02-06T00:00:00Z","timestamp":1612569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,4,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Checkpoint inhibitors (CPIs) have drastically improved metastatic cancer outcomes. However, immunotherapy is associated with multiple toxicities, including acute kidney injury (AKI). Data about CPI-related AKI are limited. Our aim was to determine risk factors for CPI-related AKI as well as its clinical characteristics and its impact on mortality in patients undergoing immunotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>All patients under CPI at our centre between March 2018 and May 2019 and with a follow-up through April 2020 were included. Demographic, clinical and laboratory data were collected. AKI was defined according to the Kidney Disease: Improving Global Outcomes guidelines. We performed a logistic regression model to identify independent risk factors for AKI and actuarial survival analysis to establish risk factors for mortality in this population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 759 patients were included, with a median age of 64\u2009years. A total of 59% were men and baseline median creatinine was 0.80\u2009mg\/dL. The most frequent malignancy was lung cancer and 56% were receiving anti-programmed death protein 1 (PD-1). About 15.5% developed AKI during the follow-up. Age and baseline kidney function were identified as independent risk factors for CPI-related AKI. At the end of follow-up, 52.3% of patients had died. The type of cancer (not melanoma, lung or urogenital malignance), type of CPI (not cytotoxic T-lymphocyte-associated protein 4, PD-1, programmed death-ligand 1 or their combination) and the presence of an episode of AKI were identified as risk factors for mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A total of 15.5% of patients under immunotherapy presented with AKI. A single AKI episode was identified as an independent risk factor for mortality in these patients and age and baseline renal function were risk factors for the development of AKI.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ndt\/gfab034","type":"journal-article","created":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T09:04:03Z","timestamp":1612515843000},"page":"887-894","source":"Crossref","is-referenced-by-count":30,"title":["Acute kidney injury as a risk factor for mortality in oncological patients receiving checkpoint inhibitors"],"prefix":"10.1093","volume":"37","author":[{"given":"Clara","family":"Garc\u00eda-Carro","sequence":"first","affiliation":[{"name":"Nephrology Department, Vall d\u2019Hebron University Hospital, Vall d\u2019Hebron Institute of Research , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica","family":"Bolufer","sequence":"additional","affiliation":[{"name":"Nephrology Department, Vall d\u2019Hebron University Hospital, Vall d\u2019Hebron Institute of Research , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana","family":"Bury","sequence":"additional","affiliation":[{"name":"Nephrology Department, Vall d\u2019Hebron University Hospital, Vall d\u2019Hebron Institute of Research , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaira","family":"Casta\u00f1eda","sequence":"additional","affiliation":[{"name":"Nephrology Department, Vall d\u2019Hebron University Hospital, Vall d\u2019Hebron Institute of Research , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Mu\u00f1oz","sequence":"additional","affiliation":[{"name":"Oncology Department, Vall d\u2019Hebron\u00a0University Hospital, Vall d\u2019Hebron Institute of Oncology , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enriqueta","family":"Felip","sequence":"additional","affiliation":[{"name":"Oncology Department, Vall d\u2019Hebron\u00a0University Hospital, Vall d\u2019Hebron Institute of Oncology , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lorente","sequence":"additional","affiliation":[{"name":"Urology Department, Vall d\u2019Hebron\u00a0University Hospital, Vall d\u2019Hebron Institute of Research , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Josep","family":"Carreras","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Vall d\u2019Hebron\u00a0University Hospital, Vall d\u2019Hebron Institute of Research , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Gabaldon","sequence":"additional","affiliation":[{"name":"Pathology Department, Vall d\u2019Hebron\u00a0University Hospital, Vall d\u2019Hebron Institute of Research , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Agraz","sequence":"additional","affiliation":[{"name":"Nephrology Department, Vall d\u2019Hebron University Hospital, Vall d\u2019Hebron Institute of Research , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Ser\u00f3n","sequence":"additional","affiliation":[{"name":"Nephrology Department, Vall d\u2019Hebron University Hospital, Vall d\u2019Hebron Institute of Research , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3621-0766","authenticated-orcid":false,"given":"Mar\u00eda Jos\u00e9","family":"Soler","sequence":"additional","affiliation":[{"name":"Nephrology Department, Vall d\u2019Hebron University Hospital, Vall d\u2019Hebron Institute of Research , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,2,6]]},"reference":[{"key":"2025102312513154900_gfab034-B1","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"2025102312513154900_gfab034-B2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/bs.acr.2019.03.002","article-title":"From immune checkpoints to vaccines: the past, present and future of cancer immunotherapy","volume":"143","author":"Osipov","year":"2019","journal-title":"Adv Cancer Res"},{"key":"2025102312513154900_gfab034-B3","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"2025102312513154900_gfab034-B4","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"2025102312513154900_gfab034-B5","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/annonc\/mdz011","article-title":"Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001","volume":"30","author":"Hamid","year":"2019","journal-title":"Ann Oncol"},{"key":"2025102312513154900_gfab034-B6","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(16)30366-7","article-title":"Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial","volume":"17","author":"Hodi","year":"2016","journal-title":"Lancet Oncol"},{"key":"2025102312513154900_gfab034-B7","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper","volume":"27","author":"Champiat","year":"2016","journal-title":"Ann Oncol"},{"key":"2025102312513154900_gfab034-B8","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"2025102312513154900_gfab034-B9","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1159\/000455014","article-title":"Adverse renal effects of immune checkpoint inhibitors: a narrative review","volume":"45","author":"Wanchoo","year":"2017","journal-title":"Am J Nephrol"},{"key":"2025102312513154900_gfab034-B10","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaa008","article-title":"Acute interstitial nephritis associated with immune checkpoint inhibitors: a single-centre experience","author":"Oleas","journal-title":"Clin Kidney J"},{"key":"2025102312513154900_gfab034-B11","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors","volume":"90","author":"Cortazar","year":"2016","journal-title":"Kidney Int"},{"key":"2025102312513154900_gfab034-B12","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaa027","article-title":"Acute tubulointerstitial nephritis induced by checkpoint inhibitors versus classical acute tubulointerstitial nephritis: are they the same disease?","author":"Draibe","journal-title":"Clin Kidney J"},{"key":"2025102312513154900_gfab034-B13","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1681\/ASN.2019070676","article-title":"Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study","volume":"31","author":"Cortazar","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"2025102312513154900_gfab034-B14","doi-asserted-by":"crossref","first-page":"e000467","DOI":"10.1136\/jitc-2019-000467","article-title":"Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes","volume":"8","author":"Meraz-Mu\u00f1oz","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025102312513154900_gfab034-B15","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.2215\/CJN.00990119","article-title":"The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors","volume":"14","author":"Seethapathy","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025102312513154900_gfab034-B16","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1093\/ndt\/gfy188","article-title":"Opening an onconephrology clinic: recommendations and basic requirements","volume":"33","author":"Cosmai","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"2025102312513154900_gfab034-B17","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.kint.2019.04.043","article-title":"Summary of the international conference on onco-nephrology: an emerging field in medicine","volume":"96","author":"Capasso","year":"2019","journal-title":"Kidney Int"},{"key":"2025102312513154900_gfab034-B18","first-page":"247","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline summary","volume":"14","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"2025102312513154900_gfab034-B19","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1681\/ASN.2009121248","article-title":"The clinical importance of nephron mass","volume":"21","author":"Luyckx","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"2025102312513154900_gfab034-B20","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1161\/01.HYP.0000198544.09909.1a","article-title":"Adult hypertension and kidney disease: the role of fetal programming","volume":"47","author":"Zandi-Nejad","year":"2006","journal-title":"Hypertension"},{"key":"2025102312513154900_gfab034-B21","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.2215\/CJN.01390118","article-title":"Duration of treatment with corticosteroids and recovery of kidney function in acute interstitial nephritis","volume":"13","author":"Fernandez-Juarez","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025102312513154900_gfab034-B22","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000486744","article-title":"Impact of recurrent acute kidney injury on patient outcomes","volume":"43","author":"Rodr\u00edguez","year":"2018","journal-title":"Kidney Blood Press Res"},{"key":"2025102312513154900_gfab034-B23","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1053\/j.ajkd.2008.11.034","article-title":"Long-term risk of mortality and other adverse outcomes after acute kidney injury: a systematic review and meta-analysis","volume":"53","author":"Coca","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"2025102312513154900_gfab034-B24","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/ki.2011.405","article-title":"Increased risk of death and de novo chronic kidney disease following reversible acute kidney injury","volume":"81","author":"Bucaloiu","year":"2012","journal-title":"Kidney Int"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfab034\/38337653\/gfab034.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/37\/5\/887\/43389767\/gfab034.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/37\/5\/887\/43389767\/gfab034.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:53:04Z","timestamp":1761238384000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/37\/5\/887\/6129779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,6]]},"references-count":24,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,2,6]]},"published-print":{"date-parts":[[2022,4,25]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfab034","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,5]]},"published":{"date-parts":[[2021,2,6]]}}}